Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance

Journal of Gastroenterology

Volumn 44, Issue 8, 2009, Pages 864-870

  Kurashige, Nao ^a   Ohkawa, Kazuyoshi ^a   Hiramatsu, Naoki ^a   Yakushijin, Takayuki ^a   Mochizuki, Kiyoshi ^a   Oze, Tsugiko ^a   Kiso, Shinichi ^a   Kanto, Tatsuya ^a   Takehara, Tetsuo ^a   Kasahara, Akinori ^a   Doi, Yoshinori ^b   Yamada, Akira ^c   Fukuda, Kazuto ^d   Oshita, Masahide ^e   Mita, Eiji ^f   Fukui, Hiroyuki ^g   Nagase, Toshihiko ^h   Yoshihara, Harumasa ⁱ   Imai, Yasuharu ^d   Kato, Michio ^j   Kashihara, Takeshi ^k   Hayashi, Norio ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Otemae Hospital   (Japan)

^c SUMITOMO HOSPITAL   (Japan)

^d IKEDA MUNICIPAL HOSPITAL   (Japan)

^e OSAKA ROSAI HOSPITAL   (Japan)

^f OSAKA NATIONAL HOSPITAL   (Japan)

^g Yao Municipal Hospital   (Japan)

^h Suita Municipal Hospital   (Japan)

ⁱ OSAKA POLICE HOSPITAL   (Japan)

^j National Hospital Organizaton Minami Wakayama Medical Center   (Japan)

^k Itami City Hospital   (Japan)

more..

Author keywords

Chronic hepatitis B; Entecavir resistance; Lamivudine resistance

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; DNA DETERMINATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS RESISTANCE;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 69349083026     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0076-0     Document Type: Article

References (23)

1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-8.
2. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-63.
3. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687-96.
4. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998;27:1670-7.
5. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30:567-72.
6. Westland CE, Yang H, Delaney WE 4th, Wulfsohn M, Lama N, Gibbs CS, et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat. 2005;12:67-73.
7. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest. 1999;103:1635-40.
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-7.
9. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16.
10. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126:81-90.
11. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126:91-101.
12. van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40:1421-5.
13. van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44:318-25.
14. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-10.
15. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-20.
16. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039-49.
17. Colonno RJ, Rose R, Pokornowski K, Baldick C, Eggers B, Yu D, et al. Four year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients. J Hepatol. 2007;46:S294. (Abst.).
18. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51:902-11.
19. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002;46:2525-32.
20. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol. 2001;34:584-6.
21. Ono Y, Onda H, Sasada R, Igarashi K, Sugino Y, Nishioka K. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res. 1983;11:1747-57.
22. Fujiyama A, Miyanohara A, Nozaki C, Toneyama T, Ohtomo N, Matsubara K. Cloning and structural analyses of hepatitis B DNAs, subtype adr. Nucleic Acids Res. 1983;11:4601-10.
23. Kobayashi M, Koike K. Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization. Gene. 1984;30:227-32.